Timothy J. Barberich
Sepracor was founded in 1984 by
its Chairman and Chief Executive Officer, Timothy Barberich.
Mr. Barberich served as President and Chief Executive Officer
from 1984 through 1999, at which time Mr. Barberich was
elected Chairman of the Board of Directors. Sepracor became
a publicly traded company in 1991 and spun out four
publicly traded companies: Chirex (which, through a series
of acquisitions, was ultimately acquired by Rhodia in 2000);
HemaSure which merged with Point Therapeutics (OTC BB: POTP.OB);
BioSepra, now known as BioSphere Medical (Nasdaq: BSMD);
and Versicor which became known as Vicuron Pharmaceuticals and which was subsequently acquired by Pfizer.
Prior to founding
Sepracor, Mr. Barberich spent 10 years at Millipore Corporation,
a Bedford, Massachusetts-based company that provides leading
separations products to diversified market segments including
the life science research, pharmaceutical, biotechnology
and electronic markets. While at Millipore, he held a variety
of marketing, sales, and general management positions. Prior
to Millipore, Mr. Barberich held project management and
research scientist positions at American Cyanamid Company.
Mr. Barberich serves as Chairman of the Board of Sepracor, and as a board member of BioSphere Medical, Point Therapeutics, PhRMA, the Pharmaceutical Research and Manufacturers of America, and Gemin X.
Back to Leadership